PayRetailers Appoints Philippe Laranjeiro as Chief Commercial Officer – to Drive Ambitious Growth Strategy
31.1.2023 11:00:00 EET | Business Wire | Press release
PayRetailers, LATAM’s leading all-in-one payment technology provider, has announced the appointment of Philippe Laranjeiro as Chief Commercial Officer (CCO). He will report to CEO Juan Pablo Jutgla, overseeing the company's commercial operations, supporting rapid growth and increasing market share – while accelerating service optimization.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230126005021/en/
Philippe Laranjeiro, Chief Commercial Officer (Photo: PayRetailers)
Fintech growth leadership
Laranjeiro joins Spain-based PayRetailers with an impressive track record in the high-growth paytech sector, with more than 20 years of experience cultivating and scaling inclusive, equitable, high-performance teams. A fintech and payments veteran, he has previously worked in leadership roles for multiple Silicon Valley companies, including Atchik, Netsize, VISA, and Citcon.
His appointment supports PayRetailers’ ongoing growth strategy in a year that has seen the company expand its footprint from seven to 11 offices, more than double its headcount to over 200, and acquire Paygol in Chile and Pago Digital in Colombia.
PayRetailers Founder and CEO, Juan Pablo Jutgla, said, "We are thrilled to add someone of Philippe’s caliber to our leadership team. He is a deeply experienced and uniquely skilled fintech leader who possesses a clear client-first mentality. His experience and expertise in commercial leadership will be invaluable as we continue to focus on growth, profitability improvement, and business performance.”
Leading LATAM’s digital transformations
A specialist in aligning talent strategy to business growth, Laranjeiro will lead PayRetailers’ sales, partnerships, customer engagement and success strategy.
Philippe Laranjeiro said, "I am excited to join the team at PayRetailers as we deploy our innovative technologies to empower merchants’ digital transformations and optimize new revenue streams.”
For more information about PayRetailers, please visit the company's website at https://payretailers.com
About PayRetailers
Founded in 2017, PayRetailers is a leading global provider of online payment services with Latin DNA. Through one direct API, one technology platform and one contract, PayRetailers offers global merchants the integration of more than 250 payment methods without the need of a local entity. PayRetailers platform provides businesses the ability to manage their payment ecosystem, analyze data, and simplify their customer experience through fully integrated solutions. PayRetailers is headquartered in Spain with regional offices in Argentina, Brazil, Chile, Colombia, Mexico, Costa Rica, Paraguay, and Peru.
Website: https://www.payretailers.com
LinkedIn: https://www.linkedin.com/company/pay-retailers/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230126005021/en/
Contact information
Press Media Department
press@payretailers.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom